2026 Q1 -tulosraportti
UUTTA
2 päivää sitten
‧34 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 094 | - | - | ||
| 609 | - | - | ||
| 18 | - | - | ||
| 609 | - | - | ||
| 609 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 498 265 | 14 498 265 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 498 265 | 14 498 265 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenHealthy rebound in Onco today, many small traders are selling off. The report clearly shows what everyone wants to see, i.e., that sales are going well and that new markets are gaining momentum. Absolutely crucial! Then Spain will catch up, there we have more fuel.
·2 t sittenInvesttech 13.05.26 Medium term Oncopeptides has broken the falling trend channel in the medium term and reacted strongly upwards. It is currently difficult to say anything about the future trend direction. The stock has formed a double-bottom formation and given a signal for further upside to 1.61 kronor. In case of a reaction back, there is now support at 1.46 kronor. The stock is approaching resistance at approximately 1.90 kronor, which could lead to a downward reaction. However, a break up through 1.90 kronor would be a buy signal. Positive volume balance indicates that volume is high on up days and low on down days, which strengthens the stock. Overall, the stock is considered technically positive in the medium term. Recommendation one to six months' horizon: Buy (Score: 78)
·3 t sittenStrange that it's going down Must go up without a doubt Maybe many are selling
·3 t sittenNo wonder.
·1 päivä sittenThe growth trend is strong even if Q4-25 spills over into Q1-26. It is still good growth if one adjusts down the figures compared to Q1-23, Q1-24 and Q1-25. Extremely pleased with the outcome and considering that it's only a few markets. It can therefore accelerate with more and more markets and even if there is an approval for broader medical application. Clearly a buying opportunity in my opinion and I continue to increase and will hold until at least 2027 regardless of short-term variations.·23 t sitten · MuokattuIt can only be assessed based on actual figures and what the company has communicated. You can send a question to Oncopeptides about the size of the order from Greece. If you don't get an answer, you as owners have reason to be concerned. If the answer is that it concerns a significant amount, it changes the entire case to the negative. Q2 will in any case be absolutely crucial for the valuation. Sequential growth is not as good as you think. Sales are basically only driven by growth in Italy. Spain is not growing, and according to the interview with Redeye, it's not just due to the strike. Germany and Greece are described as stable. It's been several years since the launch, and few new markets show strong sales. Japan is conspicuously absent, despite a long time since discussions about agreements began. To call today's levels a buying opportunity - is audacious. After approx 40% increase, it will go down. I sold with the background that growth is not as good as one wishes. Buying opportunity was at 1.30.- ·1 päivä sittenThe comment from Oncopeptides about Greece (Q4 2025) means one should be cautious about interpreting Q1 2026 as a pure acceleration quarter. See the image. The core Management's wording: "we got the volumes missing in Q4 ordered in Q1" means in practice that some orders that would normally have been booked in Q4 2025 instead came in during Q1 2026. This has two effects simultaneously: 1. Q4 2025 is underestimated – sales look weaker than the underlying demand. 1. Q1 2026 is overestimated – sales not only contain new growth, but also delayed orders. Why this creates false acceleration When comparing sequentially (Q4 → Q1), it looks like sales took a clear step up. But because the base in Q4 is artificially low and Q1 artificially high, the increase is partly an accounting/timing phenomenon. Simplified: * Q4 = "too little" * Q1 = "too much" * sequential growth = overestimated So part of the reported growth in Q1 is likely not actual demand increase, but a shift between quarters. What it means analytically This means that Q1 should not be used uncritically as a new normal level for forecasts. If, for example, 0.6–0.9 Mkr has been moved from Q4 to Q1: * Q4 should have been higher by the same amount * Q1 should have been lower by the same amount * the difference between the quarters is then exaggerated by 1.2–1.8 Mkr in total This is quite significant when quarterly revenue is around 20–30 Mkr. Conclusion The Greek comment suggests that: * the reported Q1 growth was partly temporarily boosted * the true underlying growth rate is likely somewhat lower than what Q1 suggests * Q2 2026 will be more representative for assessing whether sales are truly accelerating or if Q1 was primarily a catch-up quarter In short: Q1 2026 likely looks better than the actual run-rate, because the comparison against Q4 is skewed in both directions. https://stockanalysis.com/quote/sto/ONCO/transcripts/396020-q1-2026/·1 päivä sittenIt is only possible to assess based on actual figures and what the company has communicated. You can send a question to Oncopeptides about the size of the order from Greece. If you do not receive an answer, you as owners have reason to be concerned. If the answer is that it concerns a significant amount, it changes the entire case to the negative. Q2 will in any case be completely decisive for the valuation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
UUTTA
2 päivää sitten
‧34 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenHealthy rebound in Onco today, many small traders are selling off. The report clearly shows what everyone wants to see, i.e., that sales are going well and that new markets are gaining momentum. Absolutely crucial! Then Spain will catch up, there we have more fuel.
- ·2 t sittenInvesttech 13.05.26 Medium term Oncopeptides has broken the falling trend channel in the medium term and reacted strongly upwards. It is currently difficult to say anything about the future trend direction. The stock has formed a double-bottom formation and given a signal for further upside to 1.61 kronor. In case of a reaction back, there is now support at 1.46 kronor. The stock is approaching resistance at approximately 1.90 kronor, which could lead to a downward reaction. However, a break up through 1.90 kronor would be a buy signal. Positive volume balance indicates that volume is high on up days and low on down days, which strengthens the stock. Overall, the stock is considered technically positive in the medium term. Recommendation one to six months' horizon: Buy (Score: 78)
- ·3 t sittenStrange that it's going down Must go up without a doubt Maybe many are selling·3 t sittenNo wonder.
- ·1 päivä sittenThe growth trend is strong even if Q4-25 spills over into Q1-26. It is still good growth if one adjusts down the figures compared to Q1-23, Q1-24 and Q1-25. Extremely pleased with the outcome and considering that it's only a few markets. It can therefore accelerate with more and more markets and even if there is an approval for broader medical application. Clearly a buying opportunity in my opinion and I continue to increase and will hold until at least 2027 regardless of short-term variations.·23 t sitten · MuokattuIt can only be assessed based on actual figures and what the company has communicated. You can send a question to Oncopeptides about the size of the order from Greece. If you don't get an answer, you as owners have reason to be concerned. If the answer is that it concerns a significant amount, it changes the entire case to the negative. Q2 will in any case be absolutely crucial for the valuation. Sequential growth is not as good as you think. Sales are basically only driven by growth in Italy. Spain is not growing, and according to the interview with Redeye, it's not just due to the strike. Germany and Greece are described as stable. It's been several years since the launch, and few new markets show strong sales. Japan is conspicuously absent, despite a long time since discussions about agreements began. To call today's levels a buying opportunity - is audacious. After approx 40% increase, it will go down. I sold with the background that growth is not as good as one wishes. Buying opportunity was at 1.30.
- ·1 päivä sittenThe comment from Oncopeptides about Greece (Q4 2025) means one should be cautious about interpreting Q1 2026 as a pure acceleration quarter. See the image. The core Management's wording: "we got the volumes missing in Q4 ordered in Q1" means in practice that some orders that would normally have been booked in Q4 2025 instead came in during Q1 2026. This has two effects simultaneously: 1. Q4 2025 is underestimated – sales look weaker than the underlying demand. 1. Q1 2026 is overestimated – sales not only contain new growth, but also delayed orders. Why this creates false acceleration When comparing sequentially (Q4 → Q1), it looks like sales took a clear step up. But because the base in Q4 is artificially low and Q1 artificially high, the increase is partly an accounting/timing phenomenon. Simplified: * Q4 = "too little" * Q1 = "too much" * sequential growth = overestimated So part of the reported growth in Q1 is likely not actual demand increase, but a shift between quarters. What it means analytically This means that Q1 should not be used uncritically as a new normal level for forecasts. If, for example, 0.6–0.9 Mkr has been moved from Q4 to Q1: * Q4 should have been higher by the same amount * Q1 should have been lower by the same amount * the difference between the quarters is then exaggerated by 1.2–1.8 Mkr in total This is quite significant when quarterly revenue is around 20–30 Mkr. Conclusion The Greek comment suggests that: * the reported Q1 growth was partly temporarily boosted * the true underlying growth rate is likely somewhat lower than what Q1 suggests * Q2 2026 will be more representative for assessing whether sales are truly accelerating or if Q1 was primarily a catch-up quarter In short: Q1 2026 likely looks better than the actual run-rate, because the comparison against Q4 is skewed in both directions. https://stockanalysis.com/quote/sto/ONCO/transcripts/396020-q1-2026/·1 päivä sittenIt is only possible to assess based on actual figures and what the company has communicated. You can send a question to Oncopeptides about the size of the order from Greece. If you do not receive an answer, you as owners have reason to be concerned. If the answer is that it concerns a significant amount, it changes the entire case to the negative. Q2 will in any case be completely decisive for the valuation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 094 | - | - | ||
| 609 | - | - | ||
| 18 | - | - | ||
| 609 | - | - | ||
| 609 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 498 265 | 14 498 265 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 498 265 | 14 498 265 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
2026 Q1 -tulosraportti
UUTTA
2 päivää sitten
‧34 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenHealthy rebound in Onco today, many small traders are selling off. The report clearly shows what everyone wants to see, i.e., that sales are going well and that new markets are gaining momentum. Absolutely crucial! Then Spain will catch up, there we have more fuel.
- ·2 t sittenInvesttech 13.05.26 Medium term Oncopeptides has broken the falling trend channel in the medium term and reacted strongly upwards. It is currently difficult to say anything about the future trend direction. The stock has formed a double-bottom formation and given a signal for further upside to 1.61 kronor. In case of a reaction back, there is now support at 1.46 kronor. The stock is approaching resistance at approximately 1.90 kronor, which could lead to a downward reaction. However, a break up through 1.90 kronor would be a buy signal. Positive volume balance indicates that volume is high on up days and low on down days, which strengthens the stock. Overall, the stock is considered technically positive in the medium term. Recommendation one to six months' horizon: Buy (Score: 78)
- ·3 t sittenStrange that it's going down Must go up without a doubt Maybe many are selling·3 t sittenNo wonder.
- ·1 päivä sittenThe growth trend is strong even if Q4-25 spills over into Q1-26. It is still good growth if one adjusts down the figures compared to Q1-23, Q1-24 and Q1-25. Extremely pleased with the outcome and considering that it's only a few markets. It can therefore accelerate with more and more markets and even if there is an approval for broader medical application. Clearly a buying opportunity in my opinion and I continue to increase and will hold until at least 2027 regardless of short-term variations.·23 t sitten · MuokattuIt can only be assessed based on actual figures and what the company has communicated. You can send a question to Oncopeptides about the size of the order from Greece. If you don't get an answer, you as owners have reason to be concerned. If the answer is that it concerns a significant amount, it changes the entire case to the negative. Q2 will in any case be absolutely crucial for the valuation. Sequential growth is not as good as you think. Sales are basically only driven by growth in Italy. Spain is not growing, and according to the interview with Redeye, it's not just due to the strike. Germany and Greece are described as stable. It's been several years since the launch, and few new markets show strong sales. Japan is conspicuously absent, despite a long time since discussions about agreements began. To call today's levels a buying opportunity - is audacious. After approx 40% increase, it will go down. I sold with the background that growth is not as good as one wishes. Buying opportunity was at 1.30.
- ·1 päivä sittenThe comment from Oncopeptides about Greece (Q4 2025) means one should be cautious about interpreting Q1 2026 as a pure acceleration quarter. See the image. The core Management's wording: "we got the volumes missing in Q4 ordered in Q1" means in practice that some orders that would normally have been booked in Q4 2025 instead came in during Q1 2026. This has two effects simultaneously: 1. Q4 2025 is underestimated – sales look weaker than the underlying demand. 1. Q1 2026 is overestimated – sales not only contain new growth, but also delayed orders. Why this creates false acceleration When comparing sequentially (Q4 → Q1), it looks like sales took a clear step up. But because the base in Q4 is artificially low and Q1 artificially high, the increase is partly an accounting/timing phenomenon. Simplified: * Q4 = "too little" * Q1 = "too much" * sequential growth = overestimated So part of the reported growth in Q1 is likely not actual demand increase, but a shift between quarters. What it means analytically This means that Q1 should not be used uncritically as a new normal level for forecasts. If, for example, 0.6–0.9 Mkr has been moved from Q4 to Q1: * Q4 should have been higher by the same amount * Q1 should have been lower by the same amount * the difference between the quarters is then exaggerated by 1.2–1.8 Mkr in total This is quite significant when quarterly revenue is around 20–30 Mkr. Conclusion The Greek comment suggests that: * the reported Q1 growth was partly temporarily boosted * the true underlying growth rate is likely somewhat lower than what Q1 suggests * Q2 2026 will be more representative for assessing whether sales are truly accelerating or if Q1 was primarily a catch-up quarter In short: Q1 2026 likely looks better than the actual run-rate, because the comparison against Q4 is skewed in both directions. https://stockanalysis.com/quote/sto/ONCO/transcripts/396020-q1-2026/·1 päivä sittenIt is only possible to assess based on actual figures and what the company has communicated. You can send a question to Oncopeptides about the size of the order from Greece. If you do not receive an answer, you as owners have reason to be concerned. If the answer is that it concerns a significant amount, it changes the entire case to the negative. Q2 will in any case be completely decisive for the valuation.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 7 094 | - | - | ||
| 609 | - | - | ||
| 18 | - | - | ||
| 609 | - | - | ||
| 609 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 498 265 | 14 498 265 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 14 498 265 | 14 498 265 | 0 | 0 |